机构：[1]Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China[2]Oncology, Shanghai Chest Hospital, Shanghai, China[3]Oncology, First Hospital Affiliated to Jilin University, Changchun, China[4]Lung Cancer Medical Oncology, Sichuan Cancer Hospital, Chengdu, China四川省肿瘤医院[5]Medical Oncology, The First Hospital of China Medical University, Shenyang, China[6]Oncology, Hebei Provincial Tumor Hospital, Shijiazhuang, China河北医科大学第四医院[7]Respiratory, Shanxi Tumor Hospital, Taiyuan, China[8]Oncology, Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[9]Meidical Oncology, Xijing Hospital, 4th Military Medical University, Xi’an, China[10]Oncology, Jiangsu Cancer Institute and Hospital, Nanjing, China[11]Oncology, Tangdu Hospital, Fourth Military Medical University, Xi’an, China[12]Medical Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China[13]Imaging Diagnosis, National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China[14]Clinical Research, Peking University Clinical Research Institute, Beijing, China[15]Oncology, Nanjing Military General Hospital, Nanjing, China[16]Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China[17]Headquarter, Betta Pharmaceuticals Co.,Ltd., Hangzhou, China[18]R & D center, Betta Pharmaceuticals Co.,Ltd., Hangzhou, China
第一作者机构：[1]Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
推荐引用方式(GB/T 7714)：
Shi Y-K.,Wang L.,Han B.,et al.First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with EGFR mutation (CONVINCE)[J].ANNALS OF ONCOLOGY.2016,27:
APA：
Shi, Y-K.,Wang, L.,Han, B.,Li, W.,Yu, P....&Tan, F..(2016).First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with EGFR mutation (CONVINCE).ANNALS OF ONCOLOGY,27,
MLA：
Shi, Y-K.,et al."First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with EGFR mutation (CONVINCE)".ANNALS OF ONCOLOGY 27.(2016)
医学